Rezolute, Inc.

Rezolute, Inc. company information, Employees & Contact Information

Explore related pages

Related company profiles:

Rezolute is a late-stage rare disease company focused on significantly improving outcomes for individuals with hypoglycemia caused by hyperinsulinism (HI). For more information, visit: www.rezolutebio.com.

Company Details

Employees
75
Address
275 Shoreline Dr.,
Phone
(303) 222-2128
Email
in****@****bio.com
Industry
Biotechnology Research
NAICS
Research and Development in Biotechnology (except Nanobiotechnology)
HQ
Redwood City, California
Looking for a particular Rezolute, Inc. employee's phone or email?

Rezolute, Inc. Questions

News

Rezolute Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) - The Globe and Mail

Rezolute Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) The Globe and Mail

Rezolute, Inc. to Present at Upcoming Investor Conferences in September 2025 - Quiver Quantitative

Rezolute, Inc. to Present at Upcoming Investor Conferences in September 2025 Quiver Quantitative

Rare Disease Biotech Rezolute Lines Up Triple Conference Presence: Cantor, Morgan Stanley & HC Wainwright - Stock Titan

Rare Disease Biotech Rezolute Lines Up Triple Conference Presence: Cantor, Morgan Stanley & HC Wainwright Stock Titan

Three investor conferences Oct 22–Nov 20, 2025: Rezolute to hold one-on-one investor meetings - Stock Titan

Three investor conferences Oct 22–Nov 20, 2025: Rezolute to hold one-on-one investor meetings Stock Titan

Rezolute, Inc. Reports Q4 and Full Year Fiscal 2025 Financial Results and Updates on Ersodetug Development Progress - Quiver Quantitative

Rezolute, Inc. Reports Q4 and Full Year Fiscal 2025 Financial Results and Updates on Ersodetug Development Progress Quiver Quantitative

Rare Disease Leader Rezolute Showcases Hypoglycemia Treatment Progress at BTIG Conference - Stock Titan

Rare Disease Leader Rezolute Showcases Hypoglycemia Treatment Progress at BTIG Conference Stock Titan

Rezolute, Inc. Announces Late-Breaking Presentation of Phase 3 Study Data for Ersodetug at ENDO 2025 - Quiver Quantitative

Rezolute, Inc. Announces Late-Breaking Presentation of Phase 3 Study Data for Ersodetug at ENDO 2025 Quiver Quantitative

125K Options: Rezolute Grants Inducement Awards with $9.40 Exercise Price, 10‑Year Term - Stock Titan

125K Options: Rezolute Grants Inducement Awards with $9.40 Exercise Price, 10‑Year Term Stock Titan

Rezolute, Inc. Appoints Sunil Karnawat as Chief Commercial Officer to Advance Commercialization of ersodetug - Quiver Quantitative

Rezolute, Inc. Appoints Sunil Karnawat as Chief Commercial Officer to Advance Commercialization of ersodetug Quiver Quantitative

Rezolute Completes $45 Million Investment Round with Full Exercise of $20 Million Option - Koreabizwire

Rezolute Completes $45 Million Investment Round with Full Exercise of $20 Million Option Koreabizwire

Top Rezolute, Inc. Employees

Free Chrome Extension

Find emails, phones & company data instantly

Find verified emails from LinkedIn profiles
Get direct phone numbers & mobile contacts
Access company data & employee information
Works directly on LinkedIn - no copy/paste needed
Get Chrome Extension - Free

Aero Online

Your AI prospecting assistant